AQST: Commercial relationships that drive a manufacturing-led royalties and supply business

Aquestive Therapeutics operates a manufacturing-first, licensing-enabled business: it develops oral thin film formulations, licenses commercialization rights to regional partners, and collects manufacturing fees, license/royalty revenue and product sales for a small direct portfolio. Revenue is concentrated and contract-driven, with long-term supply agreements underpinning predictability but also creating single-counterparty exposure. Learn more at https://nullexposure.com/.

How Aquestive actually makes money — a concise commercial model

Aquestive sells value in three ways: (1) exclusive manufacturing and supply of oral thin-film products for licensees, (2) licensing intellectual property for regional commercialization and related milestone/royalty streams, and (3) direct product sales of its proprietary medicines when commercialized. The company reports manufacturing and supply as the largest revenue segment, and it describes itself as the exclusive manufacturer for its five licensed commercial products worldwide (10‑K, FY2024). Long-term supply contracts give revenue visibility for some products (notably Sympazan under Assertio supply terms), while licensing expands geographic reach without Aquestive bearing commercial go-to-market cost. For a focused investor view, see https://nullexposure.com/.

Constraints that shape revenue durability and risk

Contracting posture: Aquestive operates a mix of long-term supply agreements and licensing deals that lock in manufacturing fees and exclusivity for specific products; the company explicitly cites long-term obligations and an exclusive supply agreement with Assertio for Sympazan (10‑K, FY2024).
Customer concentration: Indivior is a critical revenue source, representing approximately 62% of revenues in 2024 and ~80% in 2023; this concentration is a primary single-counterparty risk (10‑K, FY2024).
Geographic reach with local commercialization: Revenue is both North America–weighted and global, with licensees commercializing products around the world while Aquestive retains manufacturing responsibility (10‑K, FY2024).
Role and segment orientation: The company’s business is manufacturing‑centric, with significant services and license revenue streams; Aquestive declares itself the exclusive manufacturer for its licensed products and records manufacturing and supply as the largest revenue category (10‑K, FY2024).
Maturity of relationships: Some partnerships are mature and mission‑critical — Suboxone production for Indivior has been ongoing since its commercial launch in 2010 and Aquestive notes having produced billions of doses (10‑K, FY2024).
Company-level operational items: Short-term elements like an employee stock purchase plan (two six‑month offering periods) are present but are not core to counterparty risk (10‑K, FY2024).

Customer and partner roll call — one-paragraph summaries, source by source

Below are the customer and partner mentions extracted from company filings and recent releases, each stated plainly with its source.

Sunovion Pharmaceuticals Inc.

Aquestive’s 2024 10‑K references KYNMOBI being approved in 2020 and commercially launched by Sunovion in September 2020, placing Sunovion in the company’s commercial ecosystem as a historical commercial partner for KYNMOBI-related activity (10‑K, FY2024).

Assertio Holdings, Inc. (and Otter Pharmaceuticals, LLC)

Aquestive entered a license and long‑term supply arrangement that granted Assertio (through Otter Pharmaceuticals) exclusive rights to Sympazan and designated Aquestive as the exclusive worldwide manufacturer, with manufacturing fees accruing over the term; the arrangement is detailed in the 2024 10‑K, and a 2026 GlobeNewswire release confirms Sympazan oral film product activity for Assertio in the U.S. (10‑K, FY2024; GlobeNewswire, 2026).

Otter Pharmaceuticals, LLC

Otter — Assertio’s subsidiary — is identified as the counterparty in the Sympazan license arrangement; an 8‑K filed and circulated via StockTitan highlights the Sympazan collaboration with Otter (worldwide) and Aquestive’s role as formulator and manufacturer (8‑K/StockTitan, 2026).

Zambon S.p.A. / Zambon

Aquestive licensed Exservan to Zambon for EU development and commercialization; Zambon markets the product as Emylif in Europe, a fact recorded in the 2019 license notice included in the 2024 10‑K and reiterated in a 2026 press release listing Emylif as an active oral film product (10‑K, FY2024; GlobeNewswire, 2026).

Indivior Inc. (Indivior)

Aquestive is the exclusive manufacturer of Suboxone sublingual film and states that Indivior launched Suboxone in 2010; Indivior represented roughly 62% of revenues in 2024 (80% in 2023), and a 2026 company release confirms continuation of Suboxone manufacturing for Indivior (10‑K, FY2024; GlobeNewswire, 2026).

Kaleo, Inc.

Kaleo is cited in the 2024 10‑K not as a customer but as a market participant in autoinjector devices (Auvi‑Q); the mention positions Kaleo as a peer/competitive reference in the market for needle‑based treatments rather than a direct manufacturing customer (10‑K, FY2024).

Hypera / Hypera‑Pharma (Brazil)

Aquestive licensed commercial rights to Ondif (ondansetron oral film) to Hypera for Brazil; the 10‑K lists Hypera as the Brazilian commercialization partner, and a 2026 GlobeNewswire release references Ondif oral film product activity in Brazil for Hypera (10‑K, FY2024; GlobeNewswire, 2026).

What these relationships mean for valuation and downside

Predictable fee income from supply contracts: Long‑term manufacturing agreements (explicit for Sympazan/Assertio) convert product commercialization into recurring manufacturing fees, supporting EBITDA visibility when volumes are stable.
Single‑counterparty concentration is the dominant risk: Indivior’s 62%+ share of 2024 revenue is a valuation lever — any change in that contract, pricing, or demand materially affects cash flow. This concentration drives the premium on contract renewal visibility and counterparty credit analysis (10‑K, FY2024).
Geographic and commercialization risk are transferred to licensees: Licensing deals broaden addressable markets without direct go‑to‑market expense, but payment and commercialization outcomes depend on third‑party execution. For investors, licensee sales performance and deferred revenue recognition timing are key monitors.
Operational criticality of manufacturing: As the exclusive manufacturer for multiple licensed products, Aquestive’s facility uptime, regulatory compliance and capacity utilization are strategic value drivers; any manufacturing disruption has direct revenue impact (10‑K, FY2024).

For a structured investor due‑diligence checklist and counterparty monitoring framework, review our analyst resources at https://nullexposure.com/.

Investment takeaways and action items

Monitor Indivior exposure first: track Suboxone volumes, contract renewal dates and Indivior’s own commercial performance; this single relationship determines near‑term cash flow sensitivity.
Track Assertio/Otter contract terms: long‑term supply status and manufacturing fee schedule for Sympazan provide mid‑term revenue visibility.
Watch licensee commercialization: outcomes in Brazil (Hypera) and Europe (Zambon/Emylif) shift geography‑weighted revenue and royalty timing.
Assess operational risk: investigate capacity, regulatory inspection history and contingency plans for manufacturing continuity given the company’s exclusive‑manufacturer posture.

Concluding action: for ongoing monitoring of these partner dynamics and to model revenue sensitivity under different contract outcomes, visit https://nullexposure.com/ and subscribe for updates.

Bold commercial relationships, concentrated revenue and manufacturing exclusivity are the three principal lenses for valuing Aquestive; investors should prioritize counterparty risk management and contract renewal visibility when assessing AQST.

AQST customer relationships